Last reviewed · How we verify
Abacavir/lamivudine/zidovudine
Abacavir/lamivudine/zidovudine is a Nucleoside reverse transcriptase inhibitor (NRTI) combination Small molecule drug developed by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections. It is currently FDA-approved for HIV-1 infection in treatment-naïve and treatment-experienced patients. Also known as: Trizivir, ABC/3TC/ZDV.
This combination of three nucleoside reverse transcriptase inhibitors blocks HIV reverse transcriptase to prevent viral replication.
This combination of three nucleoside reverse transcriptase inhibitors blocks HIV reverse transcriptase to prevent viral replication. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients.
At a glance
| Generic name | Abacavir/lamivudine/zidovudine |
|---|---|
| Also known as | Trizivir, ABC/3TC/ZDV |
| Sponsor | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections |
| Drug class | Nucleoside reverse transcriptase inhibitor (NRTI) combination |
| Target | HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Abacavir, lamivudine, and zidovudine are all nucleoside reverse transcriptase inhibitors (NRTIs) that work by being incorporated into the growing HIV DNA chain, causing chain termination and preventing the virus from replicating. The combination provides synergistic antiviral activity against HIV-1 by targeting the same enzyme through multiple agents simultaneously.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced patients
Common side effects
- Hypersensitivity reaction (abacavir)
- Nausea
- Headache
- Diarrhea
- Fatigue
- Anemia (zidovudine-related)
- Lactic acidosis
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2, PHASE3)
- Reverse Transcriptase Inhibitors in AGS (PHASE2)
- Research on the Psychological Status of Patients With HIV-1 Infection
- A Study of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 Years) Who Are Virologically Suppressed (PHASE2)
- A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years (PHASE2)
- Inhibition of Reverse Transcription in Aicardi-Goutières Syndrome (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Abacavir/lamivudine/zidovudine CI brief — competitive landscape report
- Abacavir/lamivudine/zidovudine updates RSS · CI watch RSS
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections portfolio CI
Frequently asked questions about Abacavir/lamivudine/zidovudine
What is Abacavir/lamivudine/zidovudine?
How does Abacavir/lamivudine/zidovudine work?
What is Abacavir/lamivudine/zidovudine used for?
Who makes Abacavir/lamivudine/zidovudine?
Is Abacavir/lamivudine/zidovudine also known as anything else?
What drug class is Abacavir/lamivudine/zidovudine in?
What development phase is Abacavir/lamivudine/zidovudine in?
What are the side effects of Abacavir/lamivudine/zidovudine?
What does Abacavir/lamivudine/zidovudine target?
Related
- Drug class: All Nucleoside reverse transcriptase inhibitor (NRTI) combination drugs
- Target: All drugs targeting HIV reverse transcriptase
- Manufacturer: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Virology
- Indication: Drugs for HIV-1 infection in treatment-naïve and treatment-experienced patients
- Also known as: Trizivir, ABC/3TC/ZDV
- Compare: Abacavir/lamivudine/zidovudine vs similar drugs
- Pricing: Abacavir/lamivudine/zidovudine cost, discount & access